Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Recent advancements suggest that a significant competitor to Keytruda, the world’s top-selling cancer therapy, might be emerging.,Keytruda, manufactured b... "Lorem ipsum dolor sit amet, consectetur ...

Ivonescimab demonstrated superior progression-free survival compared to Keytruda, positioning it as a potential leader in... ...

Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. See why I think further downside ...

The easiest way to uplift your spirits and boost your morale is by bookmarking some of the best “keep going” quotes designed to provide much-needed encouragement, confidence, and motivation.

Data from the study showed that the drug reduced the risk of disease progression or death by nearly half when compared to Keytruda. This data conforms with the initial results reported by SMMT in ...

Kodiak Gas Services, Inc. (NYSE: KGS) (“Kodiak” or the “Company”) today announced the pricing of an underwritten public offering (the ...

Merck's shares closed 2.1% lower at $115.41. Analysts, however, downplayed worries around Keytruda facing a challenge from Summit's drug as it remains years away from the market. Summit shares hit ...

Compared with Keytruda, the Summit drug ivonescimab cut the risk of disease progression or death by 49% in patients with a common type of lung cancer, Summit said in a release Sunday. Ivonescimab ...

The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...

Summit Therapeutics’s drug ivonescimab reduced the risk of lung cancer progression or death by nearly half, compared to MSD’s blockbuster drug Keytruda (pembrolizumab) in Phase III data showcased on 8 ...